{
    "nct_id": "NCT06435286",
    "official_title": "Effectiveness and Performance of a Mobile, Automated, Optical Biopsy Technology for Esophageal Cancer Screening: A Clinical Study in Brazil and the United States",
    "inclusion_criteria": "* Outpatients undergoing routine (standard of care) Lugol's chromoendoscopic screening for squamous cell neoplasia will be eligible for enrollment, including patients with a known history of head/neck squamous cell cancer; heavy smoking and alcohol, other dietary or geographic risk factors or prior dysplasia\n* Patients >18 years old.\n* Patients of any sex or gender.\n* Patients who are willing and able to give informed consent.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Allergy or prior reaction to the fluorescent contrast agent proflavine hemisulfate.\n* Patients who are unable to give informed consent.\n* Known advanced squamous cell carcinoma of the distal esophagus or dysplastic/suspected malignant esophageal lesion greater than or equal to 2 cm in size not amenable to endoscopic therapy.\n* Patient unable to undergo routine endoscopy with biopsy:\n* Women who are pregnant or breast feeding,\n* Prothrombin time greater than 50% of control; PTT greater than 50 sec, or INR greater than 2.0,\n* Inability to tolerate sedated upper endoscopy due to cardio-pulmonary instability or other significant medical issues.",
    "miscellaneous_criteria": ""
}